conviction.fyi
Independent equity research on individual companies. Every figure is sourced to a primary document, and each report ships with the model behind its estimates, so readers can change the assumptions and see how the valuation responds.
Coverage
ImmunityBio, Inc.
NASDAQ: IBRX
Q2 2026 edition · published August 4, 2026
Method
Claims are tied to filings, regulatory labels and trial registries. Each report is revised quarterly. Developments between editions appear on the report's news page, each linked to its original source.
The author holds positions in covered companies and discloses each one on the corresponding report. This is analysis rather than investment advice.